From Mutation Identification to Therapy: Discovery and Origins of the First Approved Gene Therapy in the Western World
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
On November 2, 2012, Glybera® (alipogene tipovarvec) was the first human gene therapy to receive long awaited market approval in the Western world. This important milestone is expected to open the door to additional gene therapies for the treatment of many diseases in the future. The development of this new gene therapy involved the dedicated contributions from many people from around the world
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gaudet, D., Méthot, J., Déry, S., Brisson, D., Essiembre, C., Tremblay, G., Tremblay, K., de Wal, J., Twisk, J., van den Bulk, N., et al. (2013) · Gene Therapy · doi:10.1038/gt.2012.43 · Cited by 404
Wittrup, H. H., Tybjærg-Hansen, A., & Nordestgaard, B. G. (1999) · Circulation · doi:10.1161/01.cir.99.22.2901 · Cited by 344
Severe hypertriglyceridemia and pancreatitis: presentation and management
Ewald, N., Hardt, P. D., & Kloer, H.-U. (2009) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283319a1d · Cited by 273 · cited 1×
“Pregnancy is an important trigger of pancreatitis and can be life-threatening in LPL deficiency (Ma et al. , 1993; Ewald et al. , 2009); however, for this treated patient the pregnancy went very well and she delivered a healthy baby.”
Stroes, E. S., Nierman, M. C., Meulenberg, J. J., Franssen, R., Twisk, J., Henny, C. P., Maas, M. M., Zwinderman, A. H., Ross, C., Aronica, E., et al. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.175620 · Cited by 209
Self-citationGene therapy for lipoprotein lipase deficiency
Gaudet, D., Méthot, J., & Kastelein, J. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283555a7e · Cited by 178 · cited 4×
“Overall, the treatment was well tolerated, without emerging safety concerns for over 2 years after treatment (Gaudet et al. , 2012b).”
InfluentialSelf-citationCarpentier, A. C., Frisch, F., Labbé, S. M., Gagnon, R., de Wal, J., Greentree, S., Petry, H., Twisk, J., Brisson, D., & Gaudet, D. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3002 · Cited by 165 · cited 1×
“A small follow-up clinical study was conducted in Quebec to document the postprandial effects of Glybera and collect additional efficacy and safety data using the same dose and immunosuppression regimen as before (1 · 10 12 gc/kg) (Carpentier et al. , 2012).”
Cited by
Kaufmann, K. B., Büning, H., Galy, A., Schambach, A., & Grez, M. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201202287 · Cited by 276
Lessons learned from the clinical development and market authorization of Glybera
Bryant, L. M., Christopher, D. M., Giles, A. R., Hinderer, C., Rodriguez, J. L., Smith, J. B., Traxler, E. A., Tycko, J., Wojno, A. P., & Wilson, J. M. (2013) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2013.087 · Cited by 189
“A summary of the early preclinical research forming the basis for the clinical development of this product was reviewed by the principal scientists in Human Gene Therapy (Kastelein et al., 2013).”
BackgroundMietzsch, M., Casteleyn, V., Weger, S., Zolotukhin, S., & Heilbronn, R. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.050 · Cited by 65
Nicolson, S. C., Li, C., Hirsch, M. L., Setola, V., & Samulski, R. J. (2016) · Journal of Virology · doi:10.1128/jvi.02953-15 · Cited by 48
“Indeed, clinical efficacy for one indication, lipoprotein lipase deficiency, has been achieved to the extent that the first-ever gene therapy product, an rAAV1 vector carrying a lipoprotein lipase transgene, is now approved for use in the European Union (9).”
BackgroundInfluential
Metadata
- Authors
- Kastelein, J. J. P., Ross, C. J. D., & Hayden, M. R.
- Venue
- Human Gene Therapy
- Publisher
- SAGE Publications
- Published
- 2013-05
- Volume
- 24
- Issue
- 5
- Pages
- 472-478
- ISSN
- 1043-0342 (ISSN-L)
- 1557-7422
- OpenAlex
- W1982257974
- Cited by
- 56
- References
- 6
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.